DrJanice Layhadi

Dr Janice Layhadi is a Research Associate at the Immunomodulation and Tolerance Group (ITG) of Allergy & Clinical Immunology, NHLI. She completed her undergraduate studies in Biochemistry at Imperial College London and pursued a Master's degree in Pharmacology at Oxford University. Dr Layhadi completed her PhD studies in molecular sciences and pharmacology at the University of East Anglia in 2017 and joined Professor Mohamed Shamji's group at Imperial College London.

Her research interest primarily involves identifying underpinning molecular mechanisms in innate lymphoid cells associated with immune tolerance. She has defined a new subset of innate lymphoid cells, IL-10⁺ ILC2, that are induced following allergen immunotherapy and correlate with clinical efficacy. Dr Layhadi leads the single-cell multi-omic research at ITG and has identified novel biomarkers for AIT response. Her research has resulted in more than 50 peer-reviewed publications with nearly 2,000 citations in high-impact journals within the field of Allergy. Her contribution to the field has been internationally recognised through several major awards, including the EAACI–Allergopharma Research Award (2022), the EAACI Early Career Research Award (2025), the Henning-Loewenstein Research Award (2025), and the Stallergenes Foundation Award (2025). She currently serves as Co-Chair of the European Academy of Allergy and Clinical Immunology (EAACI) Scientific Programme Committee (2026–2028).